NCT03838042 - INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions

CNS TumorSolid Tumor

Interventions

DRUG

Nivolumab and Entinostat

Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.

Trial Locations (14)

1090

RECRUITING

St. Anna Children's Hospital, Vienna

2031

RECRUITING

Sydney Children's Hospital, Randwick

2145

RECRUITING

Children's Hospital at Westmead, Westmead

3052

RECRUITING

Royal Children's Hospital, Parkville

6009

RECRUITING

Perth Children's Hospital, Nedlands

8032

RECRUITING

Children's Hospital Zurich, Zurich

69120

RECRUITING

Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg

75005

RECRUITING

Institut Curie, Paris

86156

RECRUITING

Augsburg University Hospital, Augsburg

Unknown

RECRUITING

Charité University Medicine Berlin, Berlin

RECRUITING

Essen University Hospital, Essen

RECRUITING

Hannover Medical School, Hanover

RECRUITING

Prinses Máxima Centrum, Utrecht

RECRUITING

Karolinska Institute, Stockholm

All Listed Sponsors

collaborator

German Cancer Research Center

OTHER

lead

University Hospital Heidelberg

OTHER